| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453573 | Lung Cancer | 2018 | 10 Pages |
Abstract
Despite current NCCN recommendations, the rate of INE was low for patients with stage T1 or T2 tumors. While omitting INE represents a compromise in the completeness of nodal evaluation, we found that it was not associated with a detriment in overall survival.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jeremy P. Harris, Chika Nwachukwu, Yushen Qian, Erqi Pollom, Billy W. Loo, Millie Das, Maximilian Diehn,